Sci Tech Development
Pharmaceuticals, 281 Kercheval Ave, Grosse Pointe Farms, Michigan, 48236, United States, 1-10 Employees
Phone Number: 31********
Who is SCITECH DEVELOPMENT
SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. SciTechs innovations and pipeline will impact our mission to develop cost-...
Read More
-
Headquarters: 281 Kercheval Ave, Grosse Pointe Farms, Michigan, 48236, United States
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
Industry: Pharmaceuticals
SIC Code: 2834
Does something look wrong? Fix it. | View contact records from SCITECH DEVELOPMENT
SciTech Development Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding SciTech Development
Answer: SciTech Development's headquarters are located at 281 Kercheval Ave, Grosse Pointe Farms, Michigan, 48236, United States
Answer: SciTech Development's phone number is 31********
Answer: SciTech Development's official website is https://scitechdevelopment.com
Answer: SciTech Development's revenue is $1 Million to $5 Million
Answer: SciTech Development's SIC: 2834
Answer: SciTech Development has 1-10 employees
Answer: SciTech Development is in Pharmaceuticals
Answer: SciTech Development contact info: Phone number: 31******** Website: https://scitechdevelopment.com
Answer: SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. SciTechs innovations and pipeline will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SCITECH DEVELOPMENT LLC Introducing Our Revolutionary New Drug Delivery Platform (SDP) and Lead Cancer Drug Candidate ST-001 nanoFenretinide. Our proprietary Drug Delivery Platform, called SDP, has enormous potential to develop and deliver new and better drugs for incurable cancers. ST-001-nanoFenretinide is our first, patented drug, that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. Fenretinide presents a low-risk scenario as it has been shown to be safe and effective in both children and adults in previous clinical trials. ST-001 is clinical trial ready! OUR GOAL Our immediate goal is to commercialize ST-001 and develop strategic partnerships with companies in the pharmaceutical industry who are looking to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies. OUR HIGHLIGHTS AND ACHIEVEMENTS IND for T-Cell Lymphomas approved by the FDA FDA approved Phase 1a/b (equivalent to traditional Phase 1 & 2) clinical trial plan IRB Approved by Rush University Medical Center to start clinical trials Orphan Drug Designation granted for several T-cell lymphomas SDP can be used to solve bioavailability and delivery issues in many other drugs SDP has potential application for treating additional cancers and other diseases ST-001 has potential use as a companion therapeutic with other already approved drugs Affordable treatment cost to patients and for payors
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month